BiondVax ’s Phase IIb trial for flu vaccine meets primary endpoints

Israel-based BiondVax Pharmaceuticals and the UNISEC consortium have announced positive data from the Phase IIb clinical trial of universal flu vaccine candidate, M-001.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news